We hate this three letters - NVO

=== SUMMARY === - Author argues NVO is deeply undervalued via DCF, FCFE, and Graham models, with fair value in the triple digits. - Thesis: Despite market share losses and margin compression, the GLP-1 oral pill franchise is beating LLY, and brand loyalty remains strong even in patent-expired markets. - Quality: Moderately researched DD with a high-conviction turnaround narrative, but model assumptions are not shown. === SENTIMENT === BULLISH === TRADE IDEAS === NVO - LONG | confidence: 0.72 | sentiment: +0.70 Speaker: u/Far-East-locker Thesis: 1. THE FACT: Author’s DCF/FCFE/Graham models imply triple-digit fair value, and oral prescription numbers are crushing LLY. 2. THE BRIDGE: If the turnaround is real, the market’s continued punishment of NVO creates a mispricing opportunity. 3. THE VERDICT: Long NVO as an undervalued turnaround play while sentiment remains negative. 4. RISKS: Continued share loss, deeper margin compression, generic erosion in emerging markets, or failed execution could invalidate the thesis. Timeframe: long-term Key Points: - DCF/FCFE/Graham imply high fair value - Oral prescription data vs LLY is bullish - Brand premium persists in China/India - Acknowledges share loss and margin pressure - Market continues to punish stock